Commercial molecular diagnostics firm, Lexagene Holdings Inc (OTCMKTS:LXXGF), which is engaged in selling point-of-need highly multiplexed in-clinic PCR systems in less than two hours, on September 17, 2021, announced that the firm has taken up new corporate governance policies and charters.
Dr. Jack Regan, LexaGene’s CEO and Founder said that the Board of Directors, along with the leadership team, have taken good corporate governance diligently and felt it is time to modernize them. Regan added that the company is increasing its effectiveness and proceeding in direction of accountability as well as ameliorating strategic business imperatives.
The firm’s Board also adopted a fresh audit committee charter, nominating and corporate governance charter, cyber security policy, compensation committee charter as well as code of business conduct and ethics. The policies and charters are available on its website.
Lexagene’s Board also filed and got a receipt for the final base shelf prospectus, enabling it to give $25,000,000 of common shares, warrants, debt securities, or units from time to time during the 25-month period that the Shelf Prospectus is effective. The company also filed Shelf Prospectus with the regulator in all territories as well as provinces of Canada but the specific terms will be in a prospectus supplement to the Shelf Prospectus.